- Home
- FluxMPS™ Iscove's Modified Dulbecco's Medium (IMDM), High Glucose with 25mM HEPES w/o L-Glutamine: 1X Liquid
FluxMPS™ Iscove's Modified Dulbecco's Medium (IMDM), High Glucose with 25mM HEPES w/o L-Glutamine: 1X Liquid
A Microfluidics Suitable, high-glucose Iscove's Modified Dulbecco's Medium (IMDM) re-engineered for microphysiological systems and microfluidic channels. Quadruple-stage ultra-filtration (0.1 µm ×2 + 0.04 µm ×2) targets the 0.04 µm particulate range, well below conventional 0.22 µm formulations, with an endotoxin release specification of < 0.05 EU/mL and Ultrapure Type 1 water.
- High-glucose (4500 mg/L) Iscove's Modified Dulbecco's Medium supplemented with 25 mM HEPES; formulated without L-glutamine so the end user controls glutamine supplementation
- Quadruple-stage filtration architecture (0.1 µm ×2 + 0.04 µm ×2), four validated passes, for ultra-low particulate, microchannel-safe media
- Endotoxin release specification < 0.05 EU/mL by USP <85> (Bacterial Endotoxins Test), tested per manufacturing batch
- Sodium pyruvate (110 mg/L) included as an alternate carbon source and antioxidant buffer for metabolically sensitive cultures
- Formulated with Ultrapure Type 1 water (18.2 MΩ·cm) to minimize trace-metal and organic-carbon background
- ISO Class 5 (Class 100) aseptic fill & finish under an ISO 13485:2016 quality management system
- pH, glucose concentration, salts, HEPES, and nutrient composition available on request — contact support@diagnocine.com
- Glucose4500.000 mg/L
- L-GlutamineNot included
- Sodium Pyruvate110.000 mg/L
- pH (USP <791>)7.4
- Osmolality (USP <785>)210-250 mOsm/kg H2O
- Endotoxin< 0.05 EU/mL
- FiltrationQuadruple-stage (0.1 µm ×2 + 0.04 µm ×2)
- Storage2-8°C, protected from light
- Shelf Life12 months from date of manufacture, unopened
- ShippingCold-pack
Engineered where standard 0.22 µm media fails
Conventional 0.22 µm-filtered media can carry subvisible particulates and mycoplasma-scale contaminants (mycoplasma range 0.2–0.3 µm in diameter) that accumulate in microfluidic channels, corrupt biosensor signals, and shorten perfusion runs. FluxMPS™ IMDM, High Glucose + 25mM HEPES w/o L-Glutamine is re-engineered for these microphysiological systems.[1,2]
Microchannel-safe purity
A 0.04 µm final-polish filter targets subvisible particulates per USP <788> Method 1 (light obscuration), reducing the microchannel accumulation and clogging that can degrade organ-on-a-chip experiments.
Total metabolic control
A defined carbon-source and nutrient backbone, with sodium pyruvate as an alternate substrate, supports Warburg-effect and metabolic-flux studies where standard serum-rich media confound the readout.
Ultrapure-grade water
Formulated with Ultrapure Type 1 water (18.2 MΩ·cm), reducing trace-metal and organic-carbon background in the finished medium.
Low background for imaging
Low-particulate fluid reduces the risk of scatter artifacts in confocal microscopy, biosensor readouts, and TEER measurements. This formulation contains phenol red and riboflavin, both of which contribute their own optical background; phenol-red-free custom formulations are available on request.
Rich, stable nutrient profile
IMDM's enriched amino-acid and vitamin profile, selenium, and sodium pyruvate are released on a micro-batch basis for lot-to-lot consistency.
Customization on demand
pH, glucose, salts, HEPES, and nutrient composition can be adjusted on request — contact support@diagnocine.com.
Quadruple-stage filtration system
The FluxMPS™A quadruple-stage train (0.1 µm ×2 + 0.04 µm ×2) reaches a 0.04 µm final cut-off, five times finer than the 0.22 µm membranes used for conventional sterile filtration.[2,3]
-
1
0.1 µmPrefiltration I
Large particulate and aggregate removal that extends downstream filter life and protects the first 0.04 µm cartridge.
-
2
0.04 µmFinal filtration I
First 0.04 µm pass; retains sub-micron particulates and microaggregates that pass a 0.22 µm filter.
-
3
0.1 µmPrefiltration II
Second dedicated prefilter, protecting the second 0.04 µm cartridge for redundant assurance.
-
4
0.04 µmFinal filtration II — Polish
Ultimate polishing filter; ISO Class 5 (Class 100) aseptic fill & finish.
Performance vs. conventional media
© Diagnocine® — DCP-IMDMH-Q1X
Built for microphysiological & organ-on-a-chip research
IMDM, High Glucose + 25mM HEPES w/o L-Glutamine supports rapidly proliferating, high-density cultures — from erythroid progenitors, macrophages, and B/T lymphocytes to hybridomas — and is well suited to perfused MPS, metabolic, and imaging applications.[1,4]
Automated Bioreactors & Robotics
For automated bioreactors and robotic perfusion platforms, an optional Microfluidics-plus, 10 nm (0.01 µm) ultra-filtered MPS Grade variant is available, adding 0.02 µm and 0.01 µm stages beyond the standard 0.04 µm polish.
- Total particulate exclusion for narrow microchannels and high-resolution optics
- Valve & sensor protection across long unattended runs
- Extended perfusion stability for multi-week organ-on-a-chip experiments
Inquiry Required: the optional 0.01 µm (10 nm) MPS Grade variant is made to order — contact support@diagnocine.com to request it.
Micro Physiological System (MPS) & Chip
Ultra-low-particulate fluid for perfused chips and barrier models.
Warburg Effect & Metabolic Research
Defined carbon-source backbone for tumor-metabolism studies.
iPSC-Derived Models
Consistent nutrient profile for differentiated iPSC cultures.
Endothelial & Primary Cells
Low-background medium for vessel-on-chip and primary cells.
Metabolic Flux Analysis
Clean baseline for tracer and respirometry workflows. Not compatible with Agilent Seahorse XF assays, which require bicarbonate-free, phenol red-free medium.
Microscopy & Optical Sensing
Low-particulate fluid for long-term imaging workflows.
Technical specifications
Representative specifications for DCP-IMDMH-Q1X. Values are confirmed per lot on the Certificate of Analysis.
| Parameter | Specification |
|---|---|
| Formulation | IMDM base with sodium bicarbonate, phenol red, 25 mM HEPES, calcium, magnesium, glucose (4500 mg/L) and sodium pyruvate (110 mg/L); L-glutamine not included |
| Appearance | Orange-red-colored, clear solution |
| pH USP <791> | 7.4 |
| Osmolality USP <785> | 210-250 mOsm/kg H2O |
| Glucose | 4500.000 mg/L |
| L-Glutamine | Not included |
| Sodium Pyruvate | 110.000 mg/L |
| Phenol Red | 15.000 mg/L |
| Parameter | Specification |
|---|---|
| Endotoxin USP <85> BET | < 0.05 EU/mL (batch release specification — see §Manufacturing & Compliance) |
| Sterility USP <71> | Filtered in a sterile environment. No bacterial or fungal growth observed after 14 days of incubation, per USP specification. |
| Mycoplasma | 0.1 µm mycoplasma-retentive filtration (not tested per lot) |
| Particulate ≥10 µm USP <788> | Meets USP <788> Method 1 (light obscuration) limits |
| Particulate ≥25 µm USP <788> | Meets USP <788> Method 1 (light obscuration) limits |
| Water purity | Ultrapure Type 1 (18.2 MΩ·cm) |
| Manufacturing std. ISO | ISO 13485:2016; 21 CFR Part 820 (QMSR) aligned |
| Fill environment | ISO Class 5 (Class 100) aseptic |
| Parameter | Specification |
|---|---|
| Storage temperature | 2-8°C, protected from light |
| Freeze-thaw | Avoid repeated freeze-thaw |
| Shelf life | 12 months from date of manufacture, unopened |
| Shipping condition | Cold-pack |
| CO2 requirement | ∼8% CO2 recommended (HEPES-supplemented, sodium bicarbonate-buffered system; calculated per Henderson-Hasselbalch from 36 mM NaHCO3 to maintain pH 7.4) |
| Parameter | Specification |
|---|---|
| Raw material grade | Cell-culture grade, traceable lots |
| Traceability | Full lot traceability with CoA |
| Manufacturing QMS | ISO 13485:2016 certified facility |
| UNSPSC | 41116155 — Molecular biology and cell culture growth media (UNv260801) |
| Regulatory alignment | 21 CFR Part 820 (QMSR) aligned |
| Production method | Micro-batch, ISO Class 5 fill & finish |
| Intended use | For Research Use Only (RUO) |
Full composition (mg/L)
Complete defined formulation of DCP-IMDMH-Q1X, released on a per-lot basis. All 41 components and their mg/L values are reproduced from the validated formulation.
| Component | CAS Number | mg/L |
|---|---|---|
| INORGANIC SALTS | ||
| Calcium chloride dihydrate | 10035-04-8 | 219.000 |
| Magnesium sulfate anhydrous | 7487-88-9 | 97.720 |
| Potassium chloride | 7447-40-7 | 330.000 |
| Potassium nitrate | 7757-79-1 | 0.076 |
| Sodium bicarbonate | 144-55-8 | 3024.000 |
| Sodium chloride | 7647-14-5 | 4505.000 |
| Sodium dihydrogen phosphate anhydrous | 7558-80-7 | 109.000 |
| Sodium selenite | 10102-18-8 | 0.0173 |
| Component | CAS Number | mg/L |
|---|---|---|
| AMINO ACIDS | ||
| Glycine | 56-40-6 | 30.000 |
| L-Alanine | 56-41-7 | 25.000 |
| L-Arginine hydrochloride | 1119-34-2 | 84.000 |
| L-Asparagine | 70-47-3 | 25.000 |
| L-Aspartic acid | 56-84-8 | 30.000 |
| L-Cystine dihydrochloride | 30925-07-6 | 91.240 |
| L-Glutamic acid | 56-86-0 | 75.000 |
| L-Histidine hydrochloride monohydrate | 5934-29-2 | 42.000 |
| L-Isoleucine | 73-32-5 | 104.800 |
| L-Leucine | 61-90-5 | 104.800 |
| L-Lysine hydrochloride | 657-27-2 | 146.200 |
| L-Methionine | 63-68-3 | 30.000 |
| L-Phenylalanine | 63-91-2 | 66.000 |
| L-Proline | 147-85-3 | 40.000 |
| L-Serine | 56-45-1 | 42.000 |
| L-Threonine | 72-19-5 | 95.200 |
| L-Tryptophan | 73-22-3 | 16.000 |
| L-Tyrosine disodium salt | 69847-45-6 | 104.200 |
| L-Valine | 72-18-4 | 93.600 |
| Component | CAS Number | mg/L |
|---|---|---|
| VITAMINS | ||
| Choline chloride | 67-48-1 | 4.000 |
| D-Biotin | 58-85-5 | 0.013 |
| D-Ca-Pantothenate | 137-08-6 | 4.000 |
| Folic acid | 59-30-3 | 4.000 |
| Nicotinamide | 98-92-0 | 4.000 |
| Pyridoxal hydrochloride | 65-22-5 | 4.000 |
| Riboflavin | 83-88-5 | 0.400 |
| Thiamine hydrochloride | 67-03-8 | 4.000 |
| Vitamin B12 | 68-19-9 | 0.013 |
| i-Inositol | 87-89-8 | 7.200 |
| OTHERS | ||
| D-Glucose | 50-99-7 | 4500.000 |
| HEPES | 7365-45-9 | 5958.000 |
| Phenol red sodium salt | 34487-61-1 | 15.000 |
| Sodium pyruvate | 113-24-6 | 110.000 |
Manufacturing & compliance
All final packaging, quality assurance, and testing for DCP-IMDMH-Q1X are completed at the Diagnocine R&D and Quality Testing Center; customization and assembly are performed at Diagnocine Precision, Totowa, New Jersey, USA.
ISO 13485:2016 QMS
Manufactured under an ISO 13485:2016 quality management system, 21 CFR Part 820 (QMSR) aligned.
Ultrapure Type 1 Water
Formulated with 18.2 MΩ·cm Ultrapure Type 1 water for low trace-metal and organic-carbon background.
ISO Class 5 Fill & Finish
Final 0.04 µm polish and aseptic fill performed in an ISO Class 5 (Class 100) environment.
Micro-Batch Precision
Micro-batch production with per-lot release testing for lot-to-lot consistency and traceability.
Endotoxin USP <85> BET
Bacterial endotoxin testing to a < 0.05 EU/mL release specification.
Particulate USP <788> Method 1
Subvisible particulate matter controlled to USP <788> Method 1 (light obscuration) limits.
Osmolality USP <785>
Osmolality verified per lot within the specified range.
Documentation / CoA
A Certificate of Analysis accompanies every lot with measured QC values.
- Endotoxin — LAL assay, USP <85> Bacterial Endotoxins Test; assay sensitivity 0.005 EU/mL; release specification < 0.05 EU/mL
- pH, osmolality, conductivity, appearance and clarity
- Sterility
How DCP-IMDMH-Q1X compares
DCP-IMDMH-Q1X versus conventional 0.22 µm-filtered IMDM and a standard 0.22 µm-filtered DMEM-class alternative.
| Parameter | DCP-IMDMH-Q1X (FluxMPS™) | Conventional IMDM (0.22 µm) | Standard DMEM-class (0.22 µm) |
|---|---|---|---|
| Grade | Microfluidics Suitable | Not applicable (standard 0.22 µm filtered) | Not applicable (standard 0.22 µm filtered) |
| Formulation enrichment | Iscove-enriched amino acids/vitamins + selenium, potassium nitrate; L-glutamine-free | IMDM base | DMEM base |
| Final filtration pore size | 0.04 µm (40 nm) | 0.22 µm | 0.22 µm |
| Number of filtration stages | 4 (0.1 µm ×2 + 0.04 µm ×2) | 1 | 1 |
| Mycoplasma barrier filtration | check_circle | cancel | cancel |
| Endotoxin (release specification) | < 0.05 EU/mL | Corning classical liquid media — < 0.25 EU/mL Sigma-Aldrich DMEM complete medium — ≤ 2 EU/mL Gibco classical DMEM — Not specified (recorded per lot) |
|
| USP <788> particulate compliance | check_circle | cancel | cancel |
| Water quality | Ultrapure Type 1 (18.2 MΩ·cm) | Type 1/2 | Type 1/2 |
| Manufacturing QMS | ISO 13485:2016 | Varies | Varies |
| Microfluidic channel compatibility | check_circle | Limited | Limited |
| Custom formulation | check_circle | Limited | Limited |
Comparison figures from published supplier specifications, accessed 2026-09-02. Suppliers that publish no numeric endotoxin specification are shown as "Not specified".
Frequently asked questions
Common questions about DCP-IMDMH-Q1X for microphysiological and standard cell-culture workflows.
Supporting literature
Peer-reviewed literature supporting the use of enriched, ultra-filtered media in microphysiological and metabolic research.
- Bhatia SN, Ingber DE. Microfluidic organs-on-chips. Nat Biotechnol. 2014;32(8):760-772.doi:10.1038/nbt.2989
- Ronaldson-Bouchard K, Vunjak-Novakovic G. Organs-on-a-Chip: A Fast Track for Engineered Human Tissues in Drug Development. Cell Stem Cell. 2018;22(3):310-324.doi:10.1016/j.stem.2018.02.011
- Halldorsson S, et al. Advantages and challenges of microfluidic cell culture in polydimethylsiloxane devices. Biosens Bioelectron. 2015;63:218-231.doi:10.1016/j.bios.2014.07.029
- Iscove NN, Melchers F. Complete replacement of serum by albumin, transferrin, and soybean lipid in cultures of lipopolysaccharide-reactive B lymphocytes. J Exp Med. 1978;147(3):923-933.doi:10.1084/jem.147.3.923
- Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009;324(5930):1029-1033.doi:10.1126/science.1160809
- Nikolaev M, et al. Homeostatic mini-intestines through scaffold-guided organoid morphogenesis. Nature. 2020;585(7826):574-578.doi:10.1038/s41586-020-2724-8
- Drexler HG, Uphoff CC. Mycoplasma contamination of cell cultures: Incidence, sources, effects, detection, elimination, prevention. Cytotechnology. 2002;39(2):75-90.doi:10.1023/A:1022913015916
- Booth R, Kim H. Characterization of a microfluidic in vitro model of the blood-brain barrier. Lab Chip. 2012;12(10):1784-1792.doi:10.1039/c2lc40094d
- Whitesides GM. The origins and the future of microfluidics. Nature. 2006;442(7101):368-373.doi:10.1038/nature05058
- Low LA, Mummery C, Berridge BR, et al. Organs-on-chips: into the next decade. Nat Rev Drug Discov. 2021;20(5):345-361.doi:10.1038/s41573-020-0079-3
